Expression of sclerostin scFv and the effect of sclerostin scFv on healing of osteoporotic femur fracture in rats. (Q53088327)

11 May 2018

title

Expression of sclerostin scFv and the effect of sclerostin scFv on healing of osteoporotic femur fracture in rats. (English)

1 reference

11 May 2018

0 references

Qi Yao

1

1 reference

11 May 2018

Jie Ni

2

1 reference

11 May 2018

Yu Hou

3

1 reference

11 May 2018

Lixiang Ding

4

1 reference

11 May 2018

Licheng Zhang

5

1 reference

11 May 2018

Hua Jiang

6

1 reference

11 May 2018

publication date

1 June 2014

1 reference

11 May 2018

Cell Biochemistry and Biophysics

published in

1 reference

11 May 2018

volume

69

1 reference

11 May 2018

issue

2

1 reference

11 May 2018

page(s)

229-235

1 reference

11 May 2018

https://scigraph.springernature.com/pub.10.1007/s12013-013-9787-1

exact match

0 references

cites work

Osteoporosis: now and the future

1 reference

https://api.crossref.org/works/10.1007%2FS12013-013-9787-1

Sclerostin antibody increases bone mass by stimulating bone formation and inhibiting bone resorption in a hindlimb-immobilization rat model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-013-9787-1

Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-013-9787-1

Treatment with a sclerostin antibody increases cancellous bone formation and bone mass regardless of marrow composition in adult female rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-013-9787-1

Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-013-9787-1

Sclerostin monoclonal antibody therapy with AMG 785: a potential treatment for osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-013-9787-1

Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-013-9787-1

scFv antibody: principles and clinical application

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-013-9787-1

Phage antibodies: filamentous phage displaying antibody variable domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-013-9787-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-013-9787-1

Anabolic agents and bone quality

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-013-9787-1

Targeting sclerostin as potential treatment of osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-013-9787-1

Sclerostin: current knowledge and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-013-9787-1

Tumor targeting with newly designed biparatopic antibodies directed against two different epitopes of the carcinoembryonic antigen (CEA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-013-9787-1

10.1007/S12013-013-9787-1

21 January 2018

Identifiers

DOI

1 reference

11 May 2018

PubMed ID

24254971

1 reference

11 May 2018